GlaxoSmithKline plc (ADR) (GSK) creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company operates through five segments: Global Pharmaceuticals, HIV, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas under the Sensodyne, Horlicks, Parodontax, Poligrip, Voltaren, Panadol, Otrivin, Tums, Flonase, Eno, and Theraflu brand names. GlaxoSmithKline plc offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and creams. The company has a planned partnershipwith Miltenyi Biotec GmbH to develop a cell and gene therapy automation and processing technology; and a partnership with Fimbrion Therapeutics for the development of a small molecule drug to treat prevent urinary tract infections. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Sarepta Therapeutics Inc (SRPT) focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The companys lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a planned alliance with Charleys Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research partnershipagreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. It also has a research and option agreement with Nationwide Children’s Hospital for microdystrophin gene therapy program. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.